eligibility_summary
Eligible: adults 18–45 with type 1 diabetes who can provide informed consent. Excludes women who are pregnant, lactating, or planning pregnancy, and anyone with a history of cancer, heart disease, or a recent infection.
trial_source
clinical_trials.gov from Dec 2, 2025
annotation_status
ai
ai_summary
NCT06025110 (STRIDE) tests TCD601 (siplizumab) vs placebo in adults with new-onset type 1 diabetes. TCD601 is a biological immunotherapy: a humanized monoclonal antibody against CD2. Mechanism: binds CD2 on T lymphocytes and NK cells, depleting/modulating these cells and blocking the CD2–CD58 (LFA-3) costimulatory/adhesion pathway, thereby dampening autoreactive T‑cell activation to preserve pancreatic β‑cell function. Targets: CD2+ effector/memory T cells (CD4/CD8) and NK cells, T‑cell activation/costimulation pathways involved in islet autoimmunity. Design: randomized, single-blind, placebo-controlled, 12-week dosing within a 12‑month study. Status: terminated early for business reasons (not safety/efficacy). Phase 2.